Collaborations A Long-Term Focus On Innovation
We welcome the opportunity to discuss:
Business development collaborations
In-licensing and/or Research & Development (R&D) collaborations
- Creative collaborations in emerging fields
- Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
Strategic late-stage development and commercial partnerships with other leading biopharma companies
Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe
PARTNER WITH REGENERON
Academic and research collaborations
Non-clinical research collaborations providing investigators from academic and research institutions access to our:
- Proprietary animal models, cell lines and/or other technologies
- Approved medicines or therapeutic pipeline candidates for use in non-human studies
Clinical collaborations/investigator-initiated studies (IIS) providing investigators and clinicians access to and/or funding for our:
- Approved medicines or therapeutic pipeline candidates for use in clinical, non-interventional and sample analysis studies
The Regeneron Genetics Center® collaborates with experts from a large network of institutions to facilitate discovery that will transform patient care.
Learn about RGC Collaborations
Our business development strategy
Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.
We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:
- Novel platforms that enable next-generation therapeutics
- Technologies for antibody discovery and development against new/challenging targets
- New approaches that enhance activity of tumor-directed antibodies
- Biomarker discovery and validation
- Drug delivery or formulation technologies that improve the efficacy/safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
- Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
- Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery
Some of our current collaborations include:
Antibody and immunotherapy
collaborations
Global ophthalmology
collaborations
Global manufacturing and distribution
collaboration for COVID-19 antibody
cocktail REGEN-COV™
Gene-editing technology
collaboration
RNA interference (RNAi)
therapeutics collaboration
Collaborative gene therapy
programs for hearing loss
Research collaboration on genetic
basis of familial disease
Antibody discovery
agreement
Large-scale genetic research
and sequencing effort